6jc48-1

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525763

CAS#: N/A

Description: 6jc48-1 is a novel inhibitor of Lipid II with less cytotoxicity and improved pharmacokinetic profile.


Price and Availability

Size
Price

Size
Price

Size
Price

6jc48-1 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 525763
Name: 6jc48-1
CAS#: N/A
Chemical Formula: C27H22BBr2F4NO
Exact Mass: 621.0097
Molecular Weight: 623.0906
Elemental Analysis: C, 52.05; H, 3.56; B, 1.73; Br, 25.65; F, 12.20; N, 2.25; O, 2.57


Synonym: 6jc48-1

IUPAC/Chemical Name: 2,4-Bis-(4-bromo-phenyl)-6-[2-(4-dimethylamino-phenyl)-vinyl]-pyranylium;tetrafluoroborate

InChi Key: HQIFHNMTFIBILI-SYRJXDITSA-N

InChi Code: InChI=1S/C27H22Br2NO.BF4/c1-30(2)25-14-3-19(4-15-25)5-16-26-17-22(20-6-10-23(28)11-7-20)18-27(31-26)21-8-12-24(29)13-9-21;2-1(3,4)5/h3-18H,1-2H3;/q+1;-1/b16-5+;

SMILES Code: F[B-](F)(F)F.CN(C1=CC=C(/C=C/C2=[O+]C(C3=CC=C(Br)C=C3)=CC(C4=CC=C(Br)C=C4)=C2)C=C1)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Chauhan J, Cardinale S, Fang L, Huang J, Kwasny SM, Pennington MR, Basi K, diTargiani R, Capacio BR, MacKerell AD Jr, Opperman TJ, Fletcher S, de Leeuw EP. Towards Development of Small Molecule Lipid II Inhibitors as Novel Antibiotics. PLoS One. 2016 Oct 24;11(10):e0164515. doi: 10.1371/journal.pone.0164515. eCollection 2016. PubMed PMID: 27776124; PubMed Central PMCID: PMC5077133.